The Colorado Center for Personalized Medicine (CCPM) is currently returning CYP2C19 genetic results to CCPM Biobank participants. In order to receive a CCPM Biobank pharmacogenetic test result, a participant must sign a clinical consent form agreeing that results can be placed in his or her electronic health record (EHR). After this consent form is signed, results for only the CYP2C19 genetic test result will be placed into a participant’s EHR and sent to him or her via UCHealth’s My Health Connection patient portal. Other pharmacogenetic test results will be released in a step-wise approach. Please check back frequently for updates.
No. However, CCPM has begun embedding clinical decision support (CDS) into UCHealth’s EHR to notify providers if they prescribe certain medications metabolized by CYP2C19 and the patient has a known variation in the CYP2C19 gene altering his or her metabolism in a clinically-actionable way. As of August 2019, clinical decision support is available for Clopidogrel prescribed to patients with acute coronary syndromes undergoing percutaneous coronary intervention (ACS/PCI) or Voriconazole prescribed for treatment or prophylaxis of serious fungal infections.
Please note that not all medications are metabolized by CYP2C19. For medications that are metabolized by CYP2C19, CYP2C19 genotype does not impact outcomes for all medications to the same extent, or does so in an indication-specific manner.
If you are a provider and would like detailed information about clopidogrel-CYP2C19 and EHR clinical decision support, click here.
If you are a provider and would like detailed information about voriconazole-CYP2C19 and EHR clinical decision support, clear here.
For general information about CYP2C19, click here.
The CCPM Biobank pharmacogenetic (PGx) test provides valuable insight into how a patient may respond to certain medications. Below is an example of what this report looks like in the electronic health record with detailed explanations of each area of the report.